Oncologist at @ColoradoBlood | Myeloma, Amyloid, WM, BMT, CAR-T | Opinions are my own
Joined August 2017
- Tweets158
- Following210
- Followers341
- Likes496
Peter Forsberg MD retweeted
Fun day of filming with all of these myelebrities
@MansiShahMD @JanakiramMurali @MMBaljevicMD @ForsbergMD @Zach_Avigan and Amandeep Godara. #IMS26 #mmsm
Peter Forsberg MD retweeted
This paradigm-challenging trial is 💯 accrued! Congratulations to the sites, investigators, staff and our gratitude to patients. @bhemato @ldandersonjr @nsc_natalie @SusanBal9 @CBCIDocs @rajshekharucms @huntsmanMM @RahulBanerjeeMD @DholariaMD @MMBaljevicMD @End_myeloma
Peter Forsberg MD retweeted
Join us Sept. 12 for the Denver Myeloma Roundtable to hear from leading experts about the latest in myeloma treatment and research. Patient-friendly presentations, breakout sessions & live Q&A.
📍 Sheraton Denver Downtown Hotel
🔗healthtree.org/myeloma/commu…
#Myeloma #Denver
Peter Forsberg MD retweeted
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial | Nature Medicine nature.com/articles/s41591-0…
Peter Forsberg MD retweeted
CoMMit Publication- Redefining FHR MM in the context of upfront QUAD- Ravi - 2026 - Cancer - Wiley Online Library acsjournals.onlinelibrary.wi…
Peter Forsberg MD retweeted
Join @ForsbergMD , MD, of the Colorado Blood Cancer Institute, as he discusses the evolving role of bispecific antibody therapy in multiple myeloma and strategies for expanding access to these innovative treatments in community oncology settings.
youtu.be/DmfkJOSSJCM
Peter Forsberg MD retweeted
@ForsbergMD from SCRI at @ColoradoBlood presented the OPTec/OPTal trial at ASCO 2026. Click here to learn more: ajmc.com/view/results-show-g…
#MultipleMyeloma #Hematology #ASCO2026
Peter Forsberg MD retweeted
Last call! We are approaching completion of accrual for this paradigm-challenging trial! @bhemato @ldandersonjr @DholariaMD @HealthTree @RahulBanerjeeMD @ColoradoBlood @rajshekharucms @huntsmanMM @OHSUKnight @SusanBal9 @MMBaljevicMD
Peter Forsberg MD retweeted
🧬 Can outpatient step-up dosing support broader community adoption of bispecific therapies in multiple myeloma?
At ASCO 2026, Dr. Peter Forsberg (@ForsbergMD) of Colorado Blood Cancer Institute and Sarah Cannon Research Institute (@SarahCannonDocs) shares insights from the Phase 2 OPTec/OPTal trial, a community practice-based study evaluating outpatient step-up dosing strategies for teclistamab and talquetamab.
The discussion highlights findings from the prophylactic tocilizumab arms and explores evidence-based approaches to implementing bispecific therapies in community practices.
🎥 Watch on Vumedi: tinyurl.com/3j85bftj
🔗 Explore more ASCO coverage on the Vumedi ASCO Channel: tinyurl.com/yckb6d8c
#MMSM #ASCO2026
Peter Forsberg MD retweeted
In a recent interview at #ASCO26, @ForsbergMD (@ColoradoBlood) presented findings from the OPTec/OPTal trial evaluating outpatient step-up administration of teclistamab or talquetamab with prophylactic tocilizumab in R/R #MultipleMyeloma.🩸
Click here to watch:
➡️ ow.ly/1ExJ50Z71bc
#MMsm #ImmunoOnc #HemOnc #CTSM #TrialUpdate
Peter Forsberg MD retweeted
CONGRESS | #ASCO26 | PRESENTATION
Peter Forsberg presents results from OPTec/OPTal, a phase II study evaluating outpatient step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab in patients with relapsed/refractory #MultipleMyeloma (N = 52; Tec, n = 45; Tal, n = 7).
CRS occurred in 8.9% of patients receiving Tec and 28.5% of patients receiving Tal; no Grade 3/4 CRS or ICANS was reported in either arm. The most common Grade ≥3 events across both arms were neutropenia (n = 13), sepsis (n = 4), and anemia (n = 4). The ORR was 68.9% with Tec and 71.4% with Tal.
Follow our live feed for more updates: bit.ly/4dBGu9i
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#mmsm #myeloma #MedEd #MedicalCongress @ForsbergMD @ColoradoBlood
Peter Forsberg MD retweeted
High ALC after cilta-cel treatment is associated with high risk of mortality and atypical neurologic events. Patients with elevated ALC who received 3 days of dexamethasone prophylaxis tended to have fewer neurologic events and lower mortality. Read in BA: ow.ly/Rrnn50Z5cPb
Peter Forsberg MD retweeted
LIVE FROM #ASCO2026: Rapid Oral Myeloma:
@ForsbergMD : OPTec/Optal: step-up administration of Teclistamab or Talquetamab with prophylactic tocilizumab (prophyToci) in rrMM: reduced risk of CRS by 5 folds
@DottorClaudio from @IRSTDinoAmadori: "ProphyToci can incredibly reduce risk of CRS making Tec and Tal feasible also in small hospitals and community centers" #myeloma #prophyToci #teclistamab #talquetamab #OPTec #OpTal #CRS #rrMM #bispecificantibodies
Peter Forsberg MD retweeted
Come join us right now at in Room E450 with session chairs @DrKrinaPatel Dr Brandon Blue #ASCO26 @ASCO #mmsm
@MyelomaDrKapoor @thanosdimop
Join MSK myeloma specialist @szusmani at #ASCO26 as he presents results from the phase 3 CEPHEUS study evaluating daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in transplant-ineligible patients with newly diagnosed multiple myeloma.
🕒 Sunday, May 31 | 10:21 a.m. CDT
Learn more: bit.ly/49ujp5P
Peter Forsberg MD retweeted
Published in Blood Advances: Steroid prophylaxis for excessive lymphocyte expansion after BCMA #CART in #MultipleMyeloma
Read more: bit.ly/41ZXHlZ
Peter Forsberg MD retweeted
Bispecific T-cell engagers (BiTEs) are revolutionizing Multiple Myeloma care, but community access remains a hurdle. @PeteForsbergMD from @ColoradoBlood shares how the OpTEC trial is moving Teclistamab safely to the outpatient setting.#DAVAWhistler
Peter Forsberg MD retweeted
Deep, durable remissions & a clean safety profile. Dr. @ForsbergMD @ColoradoBlood showcases iMMagine-1 Phase 2 data on anito-cel (BCMA-directed CAR-T) in RRMM: ORR 96%, sCR/CR 74%, MRD-neg 95%, 24-mo PFS 62%. Global phase 3 IMMagine-3 study underway. #DAVAWhistler
Peter Forsberg MD retweeted
Peter Forsberg, MD @ForsbergMD @ColoradoBlood reviews the expanding elranatamab program: MagnetisMM-6 shows 97% ORR with Elra+Dara+Len in TI-NDMM, plus novel combos with iberdomide (MM-30) & upcoming FASTER and ElLen trials in TE-NDMM. #DAVAWhistler
Peter Forsberg MD retweeted
"Accelerating.. bispecific adoption...is the highest impact goal that the research community can currently undertake."
@MileHighMyeloma & @LNastoupilMD talk managing access to novel agents in the community setting.
buff.ly/IuEmB39